simvastatin has been researched along with Skin Neoplasms in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Banciu, M; Licarete, E; Luput, L; Mot, AC; Patras, L; Porfire, A; Rakosy-Tican, E; Rauca, VF; Sesarman, A; Toma, VA | 1 |
| Andrades, E; Bódalo, M; Deza, G; Espadas, G; Gimeno, R; Haro, N; Hernández-Muñoz, I; Pozo, ÓJ; Pujol, RM; Sabidó, E; Segura, S; Toll, A; Torres, P | 1 |
| Dai, S; Lou, D; Wang, D; Wang, S; Wang, T; Zheng, Z | 1 |
| Chodurek, E; Pilawa, B; Zdybel, M | 1 |
| Adalsteinsson, JA; Feng, H; Hu, C; Jonasson, JG; Kristjansson, AK; Muzumdar, S; Olafsdottir, GH; Ratner, D; Silverberg, JI; Tryggvadottir, L; Ungar, J; Waldman, R; Wu, R | 1 |
| Eshita, Y; Hidano, S; Ji, RC; Kamiyama, N; Kobayashi, T; Onishi, Y | 1 |
| Agha, ME; Monaghan, SA; Swerdlow, SH | 1 |
| Imano, M; Kawashima, K; Nishida, S; Obata, N; Satou, T; Tabata, M; Takeda, T; Tsubaki, M | 1 |
| Barone, A; Cabral, C; Mare, R; Mendes, M; Paolino, D; Vitorino, C | 1 |
| Baiano, S; Barra, A; Buommino, E; De Cicco, R; De Filippis, A; Morelli, F; Spampanato, C; Zanfardino, M | 1 |
| Atil, B; Hohenegger, M; Minichsdorfer, C; Sieczkowski, E; Wasinger, C | 1 |
| Desai, M; Hedlin, H; Kapphahn, K; Manson, JA; Martin, L; Simon, M; Stefanick, ML; Strickler, H; Tang, JY; Wactawski-Wende, J; Wang, A | 1 |
| Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Clynes, M; Eustace, AJ; Glynn, SA; O'Donovan, N; O'Sullivan, D | 1 |
3 review(s) available for simvastatin and Skin Neoplasms
| Article | Year |
|---|---|
Association between statins exposure and risk of skin cancer: an updated meta-analysis.
Topics: Carcinoma, Basal Cell; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin; Skin Neoplasms | 2023 |
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2008 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
12 other study(ies) available for simvastatin and Skin Neoplasms
| Article | Year |
|---|---|
Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Liposomes; Macrophages; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxidative Stress; Simvastatin; Skin Neoplasms; Tumor Microenvironment; Xanthones | 2021 |
Loss of dyskerin facilitates the acquisition of metastatic traits by altering the mevalonate pathway.
Topics: Carcinoma, Squamous Cell; Cell Cycle Proteins; Humans; Mevalonic Acid; Nuclear Proteins; Phenotype; Simvastatin; Skin Neoplasms | 2023 |
Application of EPR spectroscopy to determine the influence of simvastatin concentration on free radicals in A-375 human melanoma malignum cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Electron Spin Resonance Spectroscopy; Free Radicals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanoma; Simvastatin; Skin Neoplasms | 2019 |
Statins are associated with increased risk of squamous cell carcinoma of the skin: a whole-population study from Iceland.
Topics: Atorvastatin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Case-Control Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iceland; Simvastatin; Skin Neoplasms | 2022 |
Role of simvastatin in tumor lymphangiogenesis and lymph node metastasis.
Topics: Animals; Lymphangiogenesis; Lymphatic Metastasis; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Simvastatin; Skin Neoplasms | 2018 |
Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Female; Hematologic Neoplasms; Humans; Middle Aged; Positron Emission Tomography Computed Tomography; Simvastatin; Skin Neoplasms; Sulfonamides | 2018 |
Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Fluvastatin; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Melanoma, Experimental; Mice, Inbred C57BL; Signal Transduction; Simvastatin; Skin Neoplasms; Tumor Burden | 2019 |
Hybrid Nanostructured Films for Topical Administration of Simvastatin as Coadjuvant Treatment of Melanoma.
Topics: Adhesives; Administration, Topical; Animals; Cell Line; Chitosan; Chlorocebus aethiops; COS Cells; Drug Carriers; Drug Liberation; Humans; Lipids; Melanoma; Melanoma, Cutaneous Malignant; Nanoparticles; Nanostructures; Particle Size; Permeability; Simvastatin; Skin; Skin Absorption; Skin Neoplasms | 2019 |
Simvastatin reduces melanoma progression in a murine model.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholesterol; Disease Progression; DNA-Binding Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanoma, Experimental; Mice; Mice, Inbred C57BL; RNA-Binding Proteins; Simvastatin; Skin Neoplasms; Survival; Survival Rate; Wound Healing | 2013 |
Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-X Protein; Binding Sites; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Melanoma; Neoplasm Metastasis; Proto-Oncogene Proteins c-bcl-2; Simvastatin; Skin Neoplasms; STAT3 Transcription Factor; Wound Healing | 2015 |
Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative.
Topics: Age Factors; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cohort Studies; Environmental Exposure; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Logistic Models; Longitudinal Studies; Lovastatin; Middle Aged; Odds Ratio; Overweight; Prospective Studies; Pyridines; Risk Factors; Simvastatin; Skin Neoplasms; Smoking; Sunlight; Vitamin D; Vitamins; White People | 2016 |
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
Topics: Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Lung Neoplasms; Male; Melanoma; Neoplasm Invasiveness; Simvastatin; Skin Neoplasms | 2008 |